Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

240.69
+3.591.51%
Post-market: 240.690.00000.00%16:54 EDT
Volume:1.63M
Turnover:393.03M
Market Cap:32.11B
PE:42.83
High:243.02
Open:235.94
Low:233.33
Close:237.10
52wk High:495.55
52wk Low:197.81
Shares:133.43M
Float Shares:133.16M
Volume Ratio:1.03
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.62
EPS(LYR):2.33
ROE:96.55%
ROA:12.34%
PB:23.72
PE(LYR):103.30

Loading ...

US Equity Markets End Higher on Microsoft's Cloud Gains, Semiconductor Rebound

MT Newswires Live
·
Jul 31

Neurocrine Biosciences Q2 Adjusted EPS Beats Expectations, Revenue Rises on Product Portfolio Growth

Reuters
·
Jul 31

Alnylam Pharmaceuticals is Maintained at Buy by Needham

Dow Jones
·
Jul 31

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-07-30

Reuters
·
Jul 31

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Benzinga Earnings
·
Jul 31

Alnylam Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Top Midday Decliners

MT Newswires Live
·
Jul 31

H.C. Wainwright Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

TIPRANKS
·
Jul 31

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE)

TIPRANKS
·
Jul 31

U.S. Stocks on the MOVE-Mastercard, Starbucks, Meta

Reuters
·
Jul 30

Stock Track | Alnylam Pharmaceuticals Plummets 27.20% in Intraday Trading After Q2 Revenue Miss and Full-Year Guidance Cut

Stock Track
·
Jul 30

Alnylam falls -25.5%

TIPRANKS
·
Jul 30

Movement Alert|Alnylam Pharmaceuticals Falls 20.29% in Regular Trading, Q2 Revenue Misses Estimates as Full-Year Guidance Cut

Market Focus
·
Jul 30

Alnylam Pharmaceuticals' Q2 Adjusted EPS, Revenue Rise; Cuts 2026 Net Product Revenue Guidance; Shares Tumble Pre-Bell

MT Newswires Live
·
Jul 30

Alnylam Pharmaceuticals Shares Down 26% Premarket After Co Trims 2026 Product Sales Forecast

THOMSON REUTERS
·
Jul 30

Alnylam Slips After Trimming 2026 Product Sales Forecast

Reuters
·
Jul 30

Alnylam Q2 Revenue Rises 67% on Increased Demand for Amvuttra

Reuters
·
Jul 30

Alnylam Q2 GAAP Net Income Swings to USD 164.49 Million; Revenue Rises 67% to USD 1.29 Billion vs Q2 FY25

Reuters
·
Jul 30

GUIDANCE: (ALNY) Alnylam Pharmaceuticals Expects 2026 Total Net Product Revenue Range $4.70B - $5.10B

MT Newswires Live
·
Jul 30

Movement Alert|Alnylam Pharmaceuticals Falls 7.45% in Pre-Market Trading, Selling Pressure on Q2 Earnings Release Day

Market Focus
·
Jul 30